|
2.4 Etiologie - Portables, ondes e-m
|
|
|
|
3.4.1 Chimioprévention - aspirine
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5. Traitements
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
Merck
KGaA, Darmstadt, Germany, and Pfizer Collaborate with Dako, an Agilent
Technologies Company, on Development of Companion Diagnostic for
Investigational anti-PD-L1 Antibody, Avelumab [Pfizer]
|
|
|
|
|
|
The
three-party agreement, signed recently, enables Dako, Merck KGaA,
Darmstadt, Germany, and Pfizer to work to develop the CDx to assess
programmed death-ligand 1 (PD-L1) protein expression levels in tumor
tissue, and its microenvironment, including tumor-associated immune
cells.
|
|
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.6 ESMO
|
|
|
Europe’s biggest cancer conference takes a big picture view of cancer drug discovery [The Institute of Cancer Research]
|
|
|
|
|
|
The
keynote speech to open the conference, delivered by Dr Margaret Foti,
Chief Executive of the American Association of Cancer Research, will
focus on new funding models for accelerating progress against cancer –
and the big picture view on how policy issues affect cancer research is
also reflected in a dedicated stream of conference sessions on clinical
trial design and cancer regulation, which runs alongside tracks which
focus on the latest research in different cancer types.
|
|
|
|
|
|
|
5.6.6 ESMO - Sein
|
|
|
|
Genetic clue to breast cancer relapses [BBC News]
|
|
|
|
|
|
Dr
Lucy Yates, clinical research oncologist from the Sanger Institute in
Cambridge, and her colleagues analysed data from the tumours of 1,000
breast cancer patients including 161 people whose cancer had recurred or
spread.
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
The 21st Century Cures Act: More Homework To Do [Health Affairs]
|
|
|
|
|
|
A
recent investigation of 54 new cancer drugs approved by the FDA over
the past decade found that 74 percent had no proof that they extended
life, and few had proof for improving quality of life. “A veneer of
innovation” is how Peter F. Thall, of MD Anderson Cancer Center in
Houston, described the reliance on surrogate endpoints such as tumor
shrinkage, or biomarkers, for drug approvals.
|
|
|
|
|
|
|
6.2 Implants mammaires
|
|
|
|
6.3 Associations
|
|
|
|
6.4 Médico-éco
|
|
|
|
6.6 Publications
|
|
|